In the last decade, several trials have evaluated autologous pDC and cDC2 vaccines in metastatic melanoma patients, as well as in combination (both pDC and cDC2 vaccination) for stage 3 melanoma and prostate cancer (136). This evidence concerns the gene PDC and melanoma.